Please login to the form below

Not currently logged in
Email:
Password:

head and neck cancer

This page shows the latest head and neck cancer news and features for those working in and with pharma, biotech and healthcare.

GSK discontinues two feladilimab trials in head and neck cancer

GSK discontinues two feladilimab trials in head and neck cancer

metastatic head and neck squamous cell carcinoma (HNSCC). ... An interim analysis of the EMERGE study found that vopratelimab in combination with Bristol Myers Squibb’s Yervoy (ipilimumab) in non-small cell lung cancer (NSCLC) patients who had

Latest news

More from news
Approximately 8 fully matching, plus 110 partially matching documents found.

Latest Intelligence

  • Case study: What we're made of Case study: What we're made of

    This could be a side effect of a condition such as stroke, motor neurone disease, multiple sclerosis, learning disability, dementia, Parkinson’s disease, head and neck injury or cancer. ... We are effectively made of water and the consequences of

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    hope was that - without the brake of PD-1 – the edited cells would attack and defeat the cancer. ... The work was reported in the journal Nature and, since then, another Chinese group has tested a similar approach in head and neck cancer.

  • Immunisation politicised Immunisation politicised

    Practitioners were concerned that a hasty introduction of the vaccine would lead to lower participation rates in cervical cancer screening programmes using the pap smear test. ... For example, the remarkable silence around the fact that some strains of

  • Pharma deals in August 2015 Pharma deals in August 2015

    virus. INO-3112 generates killer T-cell responses to HPV 16 and 18 driven tumours and is in phase I / II clinical studies for cervical and head and neck cancers. ... Acquisition ‐ company. 847. Inovio. AZ/Medimmune. INO‐3112 vaccine in P1/2 for

  • Lonafarnib: promising results in first-ever trial for progeria Lonafarnib: promising results in first-ever trial for progeria

    Lonafarnib and tipifarnib are the most successful of the FTIs, currently in Phase II development for breast cancer, and acute myeloid leukaemia and glioma, respectively. ... Development in other oncological indications (chronic myeloid leukaemia,

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Mirna hires former Pfizer director as CMO Mirna hires former Pfizer director as CMO

    Prior to this, he was director of clinical oncology at Bristol-Myers Squibb where he worked on the clinical development of Erbitux (cetuximab), which is approved for colorectal cancer and head ... and neck cancer.

  • VentiRx appoints James Kyle Bryan as chief medical officer VentiRx appoints James Kyle Bryan as chief medical officer

    During his career, Dr Bryan has focused on drug discovery in oncology, and has a medical background in haematology and oncology. ... This experience will benefit VentiRx as it prepares to advance the development of VTX-2337 for patients with ovarian

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • A stumble, but not a fall – what’s next for Opdivo?

    In this manner, it can crucially target several cancers, a property that was successfully exploited by BMS and resulted in securing FDA nods for treating non-small cell lung cancer (NSCLC) ... Rubbing salt into BMS’s wounds, Merck's  Keytruda snagged

  • ASCO 2015: What you missed in Chicago

    Specifically, we thought the checkpoint inhibitors in head and neck, lung cancer and melanoma really shone. ... Patel SP et al Mol Cancer Ther 2015[2] Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Guide
How to embrace behavioural science principles in healthcare MR...
Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...